CAMBRIDGE, Mass. & RESEARCH TRIANGLE PARK, N.C. & SEOUL, Korea--(BUSINESS WIRE)--Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced that Shaperon and Hudson Therapeutics will participate in five major international conferences this fall. With a strategic focus on securing global licensing partnerships, Shaperon and Hudson Therapeutics will actively promote its innovative clinical programs addressing significant unmet needs in atopic dermatitis, alopecia areata, and idiopathic pulmonary fibrosis, an orphan indication for human and animal health..

马萨诸塞州剑桥市和北卡罗来纳州三角研究园以及韩国首尔——（商业新闻短讯）——Hudson Therapeutics是治疗解决方案的领先创新者，也是Shaperon的美国子公司，宣布Shaperon和Hudson Therapeutics将参加今年秋季的五个主要国际会议。Shaperon和Hudson Therapeutics将以确保全球许可合作伙伴关系为战略重点，积极推动其创新的临床计划，以解决特应性皮炎，斑秃和特发性肺纤维化（人类和动物健康的孤儿指征）的重大未满足需求。。

Hudson Therapeutics and Shaperon will engage in the following events:

Hudson Therapeutics和Shaperon将参与以下活动：

- Animal Health, Nutrition and Technology Innovation Asia 2024 – October 7 – 8, 2024 / Tokyo, Japan

-2024年10月7日至8日动物健康、营养和技术创新亚洲/日本东京

- Bio Japan | Regenerative Medicine Japan | HealthTech Japan – October 9 – 11, 2024 / Tokyo, Japan

-Bio Japan |再生医学日本| HealthTech Japan–2024年10月9日至11日/日本东京

- Pharm Partnering Summit – October 16 – 17, 2024 / Boston, MA USA

-Pharm Partnering Summit–2024年10月16日至17日/美国马萨诸塞州波士顿

- Bio Europe – November 4 – 6, 2024 / Stockholm Sweden

-Bio Europe–2024年11月4日至6日/瑞典斯德哥尔摩

- 8th Dermatology Drug Development Summit – Number 12, 14, 2024

-第八届皮肤病药物开发峰会–第12、14、2024号

“At these key conferences, we aim to take a leading role in advancing our innovative therapeutic solutions, not just for humans but for veterinary medicine as well,” said Dr. Seung-Yong Seong, CEO of Shaperon. “By actively engaging with potential global partners, we intend to accelerate the commercialization and global distribution of our programs targeting idiopathic pulmonary fibrosis, alopecia areata, and atopic dermatitis, addressing clinical unmet needs in these areas.”.

Shaperon首席执行官Seung Yong-Seong博士表示：“在这些关键会议上，我们的目标是在推进我们创新的治疗方案方面发挥主导作用，不仅针对人类，而且针对兽医。”。“通过与潜在的全球合作伙伴积极合作，我们打算加速针对特发性肺纤维化，斑秃和特应性皮炎的计划的商业化和全球分发，以解决这些领域的临床未满足需求。”。

Ms. Janice Marie McCourt, CEO of Hudson Therapeutics, reinforced this initiative: “These conferences offer invaluable opportunities to drive strategic collaborations. We are actively seeking partnerships to help us bring our NanoMab-based therapies to market globally, enhancing treatment options for inflammatory and fibrotic diseases in humans and companion animals.”.

Hudson Therapeutics首席执行官Janice Marie McCourt女士强调了这一举措：“这些会议为推动战略合作提供了宝贵的机会。我们正在积极寻求合作伙伴关系，帮助我们将基于纳米单抗的疗法推向全球市场，增强人类和伴侣动物炎症和纤维化疾病的治疗选择。”。

Hudson Therapeutics and Shaperon are committed to positioning themselves at the forefront of innovation by actively pursuing global licensing strategies and building strong early-stage collaborations. This initiative-taking approach ensures their leadership in the rapidly growing autoimmune and inflammatory disease sectors.

Hudson Therapeutics和Shaperon致力于通过积极推行全球许可战略和建立强大的早期合作，将自己定位在创新的前沿。这种主动采取的方法确保了他们在快速增长的自身免疫和炎症性疾病领域的领导地位。

According to The DATA Bridge Market Research, the global market for Alopecia Areata Treatment is projected to grow from $9.58 billion in 2024 to $17.93 billion by 2031, with a Compound Annual Growth Rate (CAGR) of 17.93%.

。

Hudson Therapeutics invites interested parties to discuss partnership opportunities during the upcoming events.

Hudson Therapeutics邀请感兴趣的各方在即将到来的活动中讨论合作机会。

ABOUT SHAPERON

关于SHAPERON

Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors. Its unique mechanism of action of GPCR19-P2X7 modulation suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase.

Shaperon是一家开发新型炎性体抑制剂的临床阶段生物技术公司。它独特的GPCR19-P2X7调节作用机制通过控制炎性体的启动和激活阶段来抑制包括IL-1β，IL-18，IL-6和TNF-α在内的广谱炎性细胞因子，而常规方法旨在仅抑制激活阶段。

With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, Shaperon is currently developing multiple clinical programs in atopic dermatitis, alopecia areata, alzheimer’s disease, and COVID 19 pneumonia in addition to pre-clinical pipeline assets, focused in MASH and obesity therapeutic areas..

凭借这种最适合解决复杂免疫介导的炎症性疾病的独特而新颖的方式，Shaperon目前正在开发特应性皮炎，斑秃，阿尔茨海默氏病和新型冠状病毒肺炎的多种临床项目，以及临床前管道资产，重点放在MASH和肥胖治疗领域。。

ABOUT Hudson Therapeutics

关于Hudson Therapeutics

Hudson Therapeutics, a US subsidiary of Shaperon was founded and incorporated in the US in 2023 to lead global clinical trials, investor relations, commercial strategy, and business development of assets from Shaperon. Hudson also plans to develop Shaperon's early-stage assets in the future.

。哈德逊还计划在未来开发Shaperon的早期资产。